English
Zoom-Zoom+Black contrastBlue contrastWhite contrast

How to use the speech recognition tool?

PASS

A Post-Authorization, Multicenter, Multinational, Longitudinal,Observational Safety Registry Study for Patients Treated with Voretigene Neparvovec

A Post-Authorization, Multicenter, Multinational, Longitudinal,Observational Safety Registry Study for Patients Treated with Voretigene Neparvovec.

Type: Observational



Status of the trial: Active, Not recruiting

Orphan Drug Recognition: No

Inclusion

  • Opening Date: 2019-12-20
  • Closing Date: 2029-12-01

Criteria

Inclusion: Plan to receive or have received voretigen neparvovec in at least one eye.

Exclusion: Patient who did not receive voretigen neparvovec in at least one eye.

Children: Yes

Adults: Yes

Funder Type: industry

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: